Targeting the PI3K signaling pathway in cancer

Current Opinion in Genetics and Development

Volumn 20, Issue 1, 2010, Pages 87-90

  Wong, Kwok Kin ^a,b   Engelman, Jeffrey A ^a   Cantley, Lewis C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 75849118878     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.11.002     Document Type: Review

References (32)

1. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
2. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9 (2009) 550-562
3. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 (2006) 606-619
4. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
5. Samuels Y., and Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004) 1221-1224
6. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., and Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65 (2005) 10992-11000
7. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
8. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 (2006) 77-82
9. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
10. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
11. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68 (2008) 8022-8030. This study demonstrated that breast cancers with HER2 amplification or PIK3CA mutations are particularly sensitive to dual PI3K-mTOR inhibitors
12. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., DeFeo-Jones D., Huber H.E., and Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3 (2008) e3065. This study demonstrated that breast cancers with HER2 amplification or PIK3CA mutations are particularly sensitive to AKT inhibitors
13. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14 (2008) 1351-1356. This study demonstrated that PIK3CA is oncogenic in the murine lung epithelium and that PI3K inhibition can cause dramatic shrinkage of the PI3K driven lung cancers. In addition, the authors showed that combined PI3K and MEK inhibition in vivo is an effective treatment for KRAS mutated lung cancers
14. Ihle N.T., Lemos Jr. R., Wipf P., Yacoub A., Mitchell C., Siwak D., Mills G.B., Dent P., Kirkpatrick D.L., and Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69 (2009) 143-150
15. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., and Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129 (2007) 957-968
16. Engelman J.A., and Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14 (2008) 2895-2899
17. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., and Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105 (2008) 2070-2075
18. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043. This manuscript showed that amplification of c-MET is one of the main mechanisms of acquired resistance to EGFR TKIs in lung cancer patients whose cancer harbors EGFR kinase domain mutations
19. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104 (2007) 20932-20937
20. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118 (2008) 2609-2619
21. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., and Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
22. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., and Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15 (2009) 429-440. This paper demonstrated that the mechanism of action for trastuzumab is through disruption of the HER2/HER3 complex, and that resistance could be overcome by inhibiting the PI3K pathway
23. Yuan T.L., and Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27 (2008) 5497-5510
24. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., Garcia-Echeverria C., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106 (2009) 19503-19508
25. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., Tenen D.G., and Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4 (2007) 1669-1679 discussion 1680
26. Cragg M.S., Kuroda J., Puthalakath H., Huang D.C., and Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4 (2007) 1681-1689 discussion 1690
27. Deng J., Shimamura T., Perera S., Carlson N.E., Cai D., Shapiro G.I., Wong K.K., and Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67 (2007) 11867-11875
28. Gong Y., Somwar R., Politi K., Balak M., Chmielecki J., Jiang X., and Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4 (2007) e294
29. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., Hennessy B.T., Tseng H., Pochanard P., Kim S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16 (2009) 21-32
30. Sos M.L., Fischer S., Ullrich R., Peifer M., Heuckmann J.M., Koker M., Heynck S., Stuckrath I., Weiss J., Fischer F., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106 (2009) 18351-18356
31. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., Januario T., Savage H., Punnoose E., Truong T., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15 (2009) 4649-4664
32. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69 (2009) 565-572